SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Estey E. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia. 2000; 14: 476-479.
  • 2
    Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002; 43: 1715-1727.
  • 3
    Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004; 100: 441-454.
  • 4
    Fenaux P, Mufti G, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR): results of the AZA-001 phase III study. Blood. 2007; 110: 250a. Abstract 817.
  • 5
    Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803.
  • 6
    Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109: 52-57.
  • 7
    Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007; 109: 1133-1137.
  • 8
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
  • 9
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 10
    End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999; 17: 241-258.
  • 11
    Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17: 3631-3652.
  • 12
    End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001; 61: 131-137.
  • 13
    Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007; 21: 1964-1970.
  • 14
    Cortes JE, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor, ZARNESTRAT (R115777), in chronic myeloid leukemia and other hematological malignancies. Blood. 2003; 101: 1692-1697.
  • 15
    Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-correlative trial. Blood. 2001; 97: 3361-3369.
  • 16
    Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003; 102: 4527-4534.
  • 17
    Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007; 109: 1387-1394.
  • 18
    Martinelli G, Iacobucci I, Paolini S, Ottaviani E. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin Adv Hematol Oncol. 2008; 6: 303-310.
  • 19
    Reuter CWM, Wegner J, Morgan MA. Co-treating AML cells with FTI potentiates apoptosis induced by topoisomerase II inhibitors. Blood. 2002; 100: 542a.
  • 20
    Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG. The farnesyltransferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, Pglycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia. 2007; 21: 739-746.
  • 21
    Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol. 2004; 73: 418-426.
  • 22
    Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006; 12: 591-599.
  • 23
    Harousseau JL, Lancet JE, Reiffers J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007; 109: 5151-5156.
  • 24
    Erba HP, Kopecky KJ, Kirschbaum MH, et al. Phase II studies of different schedules of the farnesyl transferase inhibitor tipifarnib for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): a North American Intergroup study (S0432). Blood. 2007; 11: 136a.
  • 25
    Brandwein JM, Leber BF, Howson-Jan K, et al. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia. 2009; 23: 631-634.
  • 26
    Harousseau J-L, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009; 114: 1166-1173.
  • 27
    Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008; 14: 3077-3082.
  • 28
    Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008; 111: 2589-2596.
  • 29
    Rolland D, Ribrag V, Haioun C, et al. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol. 2010; 65: 781-790.